재택 감염증 검사 시장 - 전략적 인사이트와 예측(2026-2035년)

The At-Home Infectious Disease Testing Market is forecast to grow at a CAGR of 9.5%, reaching USD 10.85 billion in 2035 from USD 4.78 billion in 2026.

The global at-home infectious disease testing market is experiencing robust growth, driven by the increasing consumer preference for convenient, decentralized healthcare and significant technological advancements in rapid diagnostics. This market represents an important segment of decentralized healthcare because self-testing enables faster disease detection while reducing pressure on hospitals, clinics, and diagnostic laboratories. Demand is increasing as healthcare systems encourage community-based disease surveillance and consumers become more comfortable using home diagnostic technologies for routine health monitoring. Centralized laboratory testing creates logistical constraints because transportation delays and healthcare facility capacity frequently extend diagnostic turnaround times during periods of high disease transmission. Diagnostic companies are introducing simplified sample collection devices, smartphone-enabled result interpretation, and telehealth integration that improve user experience while expanding access to timely infectious disease diagnosis. The market strengthens public health resilience by enabling rapid identification of infectious diseases outside conventional clinical environments. Regulatory oversight, analytical accuracy, consumer confidence, and digital healthcare connectivity remain critical because infectious disease results directly influence treatment decisions, isolation measures, and disease surveillance programs.

Market Drivers

Rising Demand for Decentralized Healthcare Delivery

• Decentralized healthcare strengthens infectious disease management because patients increasingly seek diagnostic services that reduce dependence on hospitals and outpatient clinics. Demand is increasing as consumers prefer rapid home testing that minimizes travel, waiting times, and unnecessary exposure to infectious environments. Centralized diagnostic systems create operational pressure because laboratory capacity and clinical appointments become constrained during periods of elevated disease transmission. Healthcare companies are expanding home-based diagnostic portfolios, telemedicine connectivity, and digital reporting platforms that improve accessibility while supporting remote clinical decision-making. Decentralized diagnostics strengthen healthcare resilience by distributing testing capacity across community settings.

Technological Advancements in Rapid Molecular Diagnostics

• Rapid molecular diagnostics improve infectious disease detection because highly sensitive technologies enable earlier identification of pathogens with laboratory-comparable performance. Demand is increasing as healthcare providers and consumers recognize the clinical value of accurate home-based molecular testing for respiratory and sexually transmitted infections. Conventional antigen tests provide faster results but may demonstrate lower analytical sensitivity for selected pathogens because viral load varies during infection progression. Manufacturers are developing compact nucleic acid amplification systems, simplified workflows, and automated result interpretation that improve usability while supporting broader household adoption. Technological innovation strengthens confidence in at-home infectious disease testing across multiple clinical applications.

Expansion of Digital Health and Telemedicine Integration

• Digital healthcare platforms improve the value of home diagnostics because diagnostic results increasingly support immediate virtual medical consultations and treatment recommendations. Demand is increasing as consumers expect seamless integration between self-testing, electronic health records, and telehealth services. Standalone diagnostic tests provide limited clinical continuity because healthcare providers require timely access to patient-generated health information for informed medical decision-making. Diagnostic companies are integrating secure cloud reporting, smartphone applications, and telemedicine partnerships that strengthen communication while improving continuity of care. Connected digital ecosystems increase long-term utilization of home infectious disease testing services.

Increasing Preparedness for Future Infectious Disease Outbreaks

• Public health preparedness remains a strategic priority because emerging infectious diseases continue creating healthcare system challenges worldwide. Demand is increasing as governments, healthcare organizations, and consumers strengthen diagnostic readiness for future outbreaks through accessible home testing solutions. Traditional outbreak response depends heavily on centralized laboratory infrastructure because large-scale testing frequently overwhelms existing healthcare capacity. Manufacturers are expanding multiplex respiratory panels, scalable manufacturing capacity, and rapid deployment strategies that improve emergency preparedness while supporting routine disease surveillance. Long-term preparedness strengthens sustained demand beyond temporary outbreak-driven testing cycles.

Market Restraints

• Variability in user sample collection techniques may reduce diagnostic accuracy outside supervised clinical environments. Regulatory approval requirements for home-use infectious disease diagnostics increase product development timelines and commercialization costs. Limited consumer awareness regarding appropriate interpretation of positive and negative results may affect responsible clinical decision-making.

Technology and Segment Insights

By Test Type

• COVID-19 testing represents the largest segment because it established long-term consumer acceptance of self-administered infectious disease testing. Demand continues shifting toward convenient self-testing as households maintain preparedness for seasonal outbreaks and symptomatic evaluation. Influenza testing is gaining traction for differentiating seasonal respiratory infections. HIV testing and sexually transmitted infection (STI) testing are significant and growing segments, driven by the demand for privacy and convenience. Hepatitis testing and Respiratory Syncytial Virus (RSV) testing represent important applications. Manufacturers are expanding test portfolios and improving digital result reporting.

By Technology

• Antigen-based testing represents the most widely adopted technology because it delivers rapid results through simple workflows suitable for home use. Consumers prioritize affordability, convenience, and immediate diagnostic information. Molecular (PCR/NAAT) testing is expanding as technologies become more compact and user-friendly, offering higher sensitivity. Antibody testing supports seroprevalence studies and infection history assessment. Isothermal amplification testing is an emerging technology offering molecular-level accuracy with simpler instrumentation. Manufacturers are improving assay sensitivity, test design, and digital interpretation systems.

By Distribution Channel

• Online pharmacies dominate the distribution landscape because digital purchasing provides convenient access without requiring physical retail visits. Demand is increasing as consumers prefer home delivery and integrated digital healthcare experiences. Retail pharmacies remain important for immediate access. Hospital and diagnostic networks facilitate integration with clinical care. Direct-to-consumer company websites are a growing channel, enabling direct brand engagement and subscription models.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic companies and specialized point-of-care testing providers. Abbott Laboratories maintains a leading position through its extensive diagnostic expertise, global manufacturing, and broad portfolio of rapid diagnostic solutions. F. Hoffmann-La Roche Ltd. differentiates itself through advanced molecular diagnostics expertise and integrated digital healthcare solutions. Siemens Healthineers AG leverages its diagnostic technologies and digital health infrastructure to support decentralized infectious disease management. Becton, Dickinson and Company (BD) differentiates itself through expertise in specimen collection and diagnostic instrumentation. OraSure Technologies, Inc. specializes in non-invasive specimen collection and rapid diagnostics. QuidelOrtho Corporation combines rapid diagnostic innovation with expertise in respiratory infectious disease detection. bioMerieux SA specializes in infectious disease diagnostics and microbiology. Hologic, Inc. brings advanced molecular diagnostic technologies and women's health expertise.
• Strategic developments include increasing integration of multiplex testing platforms capable of identifying multiple respiratory pathogens, expansion of molecular home-testing technologies, and strengthening of digital health and telemedicine connectivity. Companies are forming partnerships to improve clinical validation and expand distribution. Product launches focus on simplified sample collection, smartphone-enabled result interpretation, and connected reporting. Companies that successfully combine laboratory-quality accuracy, intuitive product design, and secure digital integration are expected to strengthen their competitive positions.

Conclusion

• The at-home infectious disease testing market is poised for significant growth, driven by the demand for decentralized healthcare, technological advancements, and increasing public health preparedness. The evolution from emergency pandemic response toward routine, connected, and multiplexed home diagnostics is reshaping the market. Companies that successfully deliver accurate, user-friendly, and digitally integrated testing solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding consumer acceptance will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. At-Home Infectious Disease Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Home Diagnostics Landscape
• 3.8 Consumer Adoption Analysis
• 3.9 Point-of-Care & Self-Testing Ecosystem
• 3.10 Digital Health & Telemedicine Integration
• 3.11 Public Health Preparedness Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Advances in Rapid Diagnostic Technologies
• 6.2 Molecular At-Home Testing
• 6.3 Artificial Intelligence in Digital Diagnostics
• 6.4 Smartphone-Based Result Interpretation
• 6.5 Multiplex Infectious Disease Testing
• 6.6 Connected Home Diagnostics Platforms
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Emergency Use & Approval Pathways
• 7.3 Quality Standards and Compliance

8. At-Home Infectious Disease Testing Market Landscape Analysis

• 8.1 Analysis by Test Type
• 8.2 Analysis by Technology
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Distribution Channel
• 8.5 Analysis by End User

9. At-Home Infectious Disease Testing Market Segment Analysis (2021-2035)

• 9.1 By Test Type
  • 9.1.1 COVID-19 Testing
  • 9.1.2 Influenza Testing
  • 9.1.3 HIV Testing
  • 9.1.4 Sexually Transmitted Infection (STI) Testing
  • 9.1.5 Hepatitis Testing
  • 9.1.6 Respiratory Syncytial Virus (RSV) Testing
  • 9.1.7 Other Infectious Disease Tests
• 9.2 By Technology
  • 9.2.1 Antigen-Based Testing
  • 9.2.2 Molecular (PCR/NAAT) Testing
  • 9.2.3 Antibody Testing
  • 9.2.4 Isothermal Amplification Testing
• 9.3 By Distribution Channel
  • 9.3.1 Online Pharmacies
  • 9.3.2 Retail Pharmacies
  • 9.3.3 Hospital & Diagnostic Networks
  • 9.3.4 Direct-to-Consumer Company Websites
• 9.4 By End User
  • 9.4.1 Adults
  • 9.4.2 Pediatric Population
  • 9.4.3 Geriatric Population

10. At-Home Infectious Disease Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. At-Home Infectious Disease Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 China
• 11.10 Japan
• 11.11 South Korea
• 11.12 India
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers, Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches & Regulatory Approvals

13. Company Profiles

• 13.1 Abbott Laboratories
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 Siemens Healthineers AG
• 13.4 Becton, Dickinson and Company (BD)
• 13.5 OraSure Technologies, Inc.
• 13.6 QuidelOrtho Corporation
• 13.7 bioMerieux SA
• 13.8 Hologic, Inc.
• 13.9 Lucira Health (Pfizer Inc.)
• 13.10 Cue Health Inc.
• 13.11 SD Biosensor, Inc.
• 13.12 ACON Laboratories, Inc.
• 13.13 Ellume Limited
• 13.14 Everly Health, Inc.
• 13.15 LetsGetChecked

14. At-Home Infectious Disease Testing Market Commercial Forecast Analysis

• 14.1 Respiratory Infection Testing
• 14.2 Sexually Transmitted Infection Testing
• 14.3 Blood-Borne Infection Testing
• 14.4 Multiplex Infectious Disease Testing
• 14.5 Digital Self-Testing Services

15. Investment & Funding Analysis

• 15.1 Venture Capital & Private Equity Trends
• 15.2 Government Funding & Public Health Initiatives
• 15.3 R&D Investment Trends

16. Future Outlook

• 16.1 Emerging Growth Opportunities
• 16.2 Future Technology & Market Trends